Strand Therapeutics
Matthew studied Biomedical Engineering with a concentration in Nanotechnology at Boston University in 2022, taking graduate courses that covered nanoparticles, DNA/RNA manipulation, and how to utilize thermodynamics for nanomedicine. He gained hands-on experience in researching and formulating nanoparticles for the delivery of a small molecule drug that would treat Age Related Macular Degeneration (AMD). This experience exposed him as to how important delivery vehicles are for effective therapeutics and led him to his role at Greenlight Biosciences, performing research and process development for Lipid Nanoparticles (LNPs) for the delivery of mRNA.
This person is not in the org chart
Strand Therapeutics
3 followers
Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics.